Yunmeng Liu | Immunotherapy | Best Researcher Award

Assist. Prof. Dr. Yunmeng Liu | Immunotherapy | Best Researcher Award

University of Arkansas for Medical Sciences | United States

Dr. Yunmeng Liu is a highly accomplished biomedical scientist and pharmacologist specializing in the interplay between immunity, metabolism, and cardiovascular health. With a robust academic foundation in molecular biology and integrated biomedical science, Dr. Liu has devoted her career to unraveling the cellular and molecular mechanisms underlying hypertension, diabetes, and related cardiovascular complications. She currently serves as a Research Assistant Professor in the Department of Pharmacology and Toxicology at UAMS, where she leads innovative projects exploring the immune system’s role in metabolic and cardiovascular diseases. Her research integrates advanced techniques in pharmacology, immunology, and molecular biology to develop new therapeutic strategies for complex chronic conditions.Dr. Liu’s extensive research contributions are reflected in numerous high-impact publications. She has investigated P2X7-mediated activation of CD8+ T cells and their role in promoting salt-sensitive hypertension, providing critical insights into the immune modulation of blood pressure. Her work on interferon gamma pathways enhancing CD8 T cell interactions in hypertension and the stimulation of the Na-Cl co-transporter NCC by CD8+ T cells in distal convoluted tubules highlights the molecular crosstalk between immune cells and renal physiology. She has also explored immune dysregulation connecting type 2 diabetes and cardiovascular complications, emphasizing how chronic metabolic imbalances influence immune cell behavior and disease progression.Other notable contributions include the role of KATP channel openers in inhibiting lymphatic contractions and lymph flow as a mechanism of peripheral edema, and Eplerenone-mediated attenuation of fibrosis in the contralateral kidney by preventing macrophage-to-myofibroblast transition, which underscore her translational approach bridging basic research and clinical relevance. Additionally, she has advanced knowledge on resident-memory T cell establishment anchoring hypertension in the kidney and the nutrition impact on diabetes and cardiovascular health, reflecting her commitment to holistic understanding of disease mechanisms.Beyond her research, Dr. Liu is deeply engaged in education and mentorship, instructing graduate students in courses such as cell biology, pathologic basis of disease, and pharmacology and therapeutics, while supervising numerous PhD and undergraduate students in cutting-edge biomedical research projects. Her scholarly excellence is recognized through awards, grant funding, and memberships in professional societies including the American Heart Association, American Diabetes Association, and American Association of Immunologists, solidifying her status as a leading expert in immunopharmacology and cardiovascular-metabolic research.

Profile: Orcid

Featured Publications

Deck, K., Mora, C., Deng, S., Rogers, P., Rafferty, T., Palade, P. T., Mu, S., & Liu, Y. (2025). Immune dysregulation connecting type 2 diabetes and cardiovascular complications. Life, 15(8), 1241.

Liu, Y. (2024, May 29). Immune disorders connecting type 2 diabetes and cardiovascular complications [Preprint].

Benson, L., Deck, K., Mora, C., Guo, Y., Rafferty, T. M., Li, L.-X., Huang, L., Qin, Z., Andrews, J. T., & Liu, Y. (2024, January 9). P2X7-mediated antigen-independent activation of CD8 T cells promotes salt-sensitive hypertension. Hypertension (Dallas, Tex.: 1979).

Benson, L. N., Guo, Y., Deck, K., Mora, C., Liu, Y., & Mu, S. (2023, March 9). The link between immunity and hypertension in the kidney and heart. Frontiers in Cardiovascular Medicine, 10, 1129384.

Benson, L. N., Liu, Y., Deck, K., Mora, C., & Mu, S. (2022, October 26). IFNγ contributes to the immune mechanisms of hypertension. Kidney360, 3(10), 1234–1246.

Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Dr. Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Licenced Physician with a doctoral degree (MD) at Department of Medicine V, University Hospital, LMU Munich | Germany

Dr. med. Laura Lambrecht, born in Munich, is a dedicated physician specializing in pneumology and cardiology with a strong research background in experimental adult cardiology. She completed her medical studies at Ludwig-Maximilians-Universität München and the Technical University of Munich, earning her approbation as a physician. Her doctoral research at the Deutsches Herzzentrum München focused on the functional impact of acetylsalicylic acid on platelet function in carriers of genetic variants in the GUCY1A1 gene, associated with coronary heart disease risk. She actively contributes to clinical work, academic research, and professional leadership roles, while also engaging in cultural and educational initiatives.

Publication Profile 

Orcid

Education 

Dr. Laura Lambrecht earned her Allgemeine Hochschulreife from Max-Bon-Gymnasium Germering with top marks. She began her pre-clinical medical studies at Ludwig-Maximilians-Universität München, achieving “gut” in her first medical examination. She continued her clinical medical studies at the Technical University of Munich, also earning “gut,” and successfully passed her second and third medical examinations. She obtained her approbation as a physician in December. Her doctoral work at the Deutsches Herzzentrum München investigated the effects of acetylsalicylic acid on platelet function in genetically predisposed individuals. She holds certifications in Good Clinical Practice (GCP) and is a member of the Young-DZHK research network.

Experience 

Dr. Lambrecht is currently a physician in training for pneumology at the LMU Klinikum, with a prior rotation in cardiology at the same institution. She has also served as a cardiology trainee at the Medizinisches Versorgungszentrum Dachau, a teaching practice of LMU Munich. Her research experience includes experimental adult cardiology at the Deutsches Herzzentrum München in the group of Prof. Dr. H. Schunkert. She has held leadership roles such as assistant representative at the LMU Klinikum. Alongside her clinical career, she has been actively involved in student representation, faculty governance, and medical community engagement through various institutional committees and organizations.

Awards and Honors 

Dr. Lambrecht’s academic achievements include graduating from Max-Bon-Gymnasium Germering with “sehr gut” and consistently strong performance in her medical studies at LMU and TU Munich. She earned her approbation as a physician and secured a place in the prestigious Young-DZHK network, reflecting her recognized potential in cardiovascular research. She received funding for her doctoral project examining the genetic and pharmacological interplay in coronary heart disease. Her leadership as assistant representative and elected student council member also reflects peer recognition. Her commitment to academic excellence, research innovation, and community service positions her as a promising contributor to both clinical and research fields.

Research Focus 

Dr. Lambrecht’s primary research interest lies in cardiovascular pharmacogenetics, particularly the influence of genetic variants on drug response. Her doctoral project focused on the functional effects of acetylsalicylic acid on platelet function in carriers of genetic variants in the coronary heart disease risk gene GUCY1A1. She is interested in translating molecular findings into personalized therapeutic strategies for cardiovascular patients. Her work integrates clinical cardiology with laboratory-based functional assays to better understand genotype-specific treatment responses. Additionally, she engages in interdisciplinary collaboration between cardiology and pneumology, aiming to address comorbid conditions and improve patient care through evidence-based, precision medicine approaches.

Publication Top Notes

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.